Below are the follow-ups from the March 16th, 2023 Quality Council Meeting with status updates and responses:

Follow-Up	Status update/response
Prior to the next meeting, Bailit Health will	OHS has reached out to a few payers to inquire about denominator size for Follow-
collect information on Follow-Up After	up After Emergency Department Visit for Mental Illness by Advanced Network.
Emergency Department Visit for Mental Illness's	
denominator size and check if ED visit	OHS is determining if/when ED visit information will be available through
information is available through Connie.	Connie.
OHS will clarify for insurers that the <i>Health</i>	OHS sent communication to insurers with this clarification.
Equity measure was intended to be	
implemented in two phases, starting with	
collecting REL data and stratifying the	
measures before moving towards paying for	
closing gaps in performance.	
Bailit Health will confirm why <i>Pediatric</i>	The Annual Pediatric Hemoglobin A1C Testing measure was retired from the 2014
Hemoglobin A1C Testing was retired in 2014.	Child Core Set because it affected a small number of children, had a weak
	evidence base, and was approaching the improvement ceiling. Please see footnote
	q on page 5 of this documentation from CMS:
	https://www.medicaid.gov/medicaid/quality-of-care/downloads/core-set-
	history-table.pdf.
Bailit Health will bring Massachusetts'	Bailit Health will bring Behavioral Health Risk Assessment Screening (for pregnant
maternity measure to the Quality Council for	women) to the Quality Council for consideration at the end of the annual review.
its consideration at the end of the annual	
review.	
Bailit Health will share Massachusetts' opioid	First, as a reminder, the opioid measures currently in the Connecticut Aligned
measure task force research with the	Measure Set are as follows:
interested Quality Council members	1. Concurrent Use of Opioids and Benzodiazepines (Pharmacy Quality Alliance)
	2. Use of Pharmacotherapy for Opioid Use Disorder (CMS)
	3. Substance Use Assessment in Primary Care (Inland Empire Health Plan)
	Below is a summary of recommendations from Massachusetts Substance Use
	Treatment Measures Work Group. Please see Slides 18-25 of this <u>presentation</u> for
	the topline recommendations and rationale presented to MA Quality Measure
	Alignment Taskforce.

## 1. Measures reviewed by the Massachusetts Task Force:

- a. Alcohol and Drug Misuse: Screening, Brief Intervention and Referral for Treatment (Oregon Health Authority)
- b. Continuity of Pharmacotherapy for Opioid Use Disorder (CMS)
- c. Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (NCQA)
- d. Risk of Continued Opioid Use Disorder (NCQA)
- e. Substance Use Assessment in Primary Care (Inland Empire Health Plan)
- f. Substance Use Disorder Treatment Penetration (Washington DSHS)
- g. Unhealthy Alcohol and Drug Use Screening and Brief Counseling (AMA-PCPI)

## 2. Measures the Task Force <u>recommended against inclusion</u> in the Massachusetts Aligned Measure Set:

- a. Alcohol and Drug Misuse: Screening, Brief Intervention and Referral for Treatment (Oregon Health Authority)
- b. Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (NCQA)
- c. Risk of Continued Opioid Use Disorder (NCQA)
- d. Substance Use Disorder Treatment Penetration (Washington DSHS)
- e. Unhealthy Alcohol and Drug Use Screening and Brief Counseling (AMA-PCPI)

## 3. Measures the Task Force <u>recommended for inclusion</u> in the Massachusetts Aligned Measure Set:

- a. Substance Use Assessment in Primary Care (Inland Empire Health Plan)
- b. Continuity of Pharmacotherapy for Opioid Use Disorder (CMS)